生物标志物提升2型心肌梗死的鉴别与预后评估
基于CHOPIN研究回顾性分析2071例急诊胸痛患者,其中T1MI 94例、T2MI 176例。CT-proET1、MR-proADM和MR-proANP鉴别T2MI的AUC高于cTnI,联合所有生物标志物与临床模型联合cTnI的鉴别效能相似。除cTnI外,其他生物标志物均与180天全因死亡和MACE独立相关,且不受MI类型影响。
要点
- CT-proET1、MR-proADM和MR-proANP鉴别T2MI的AUC分别为0.765、0.750和0.733,均高于cTnI的0.631。
- 生物标志物联合临床模型鉴别T2MI的AUC最高达0.917。
- 除cTnI外,其他生物标志物与180天死亡和MACE相关,且与MI类型无交互作用。
核心结论
- 反映T2MI病理生理过程的生物标志物有助于将其与T1MI鉴别。
- 除cTnI外,所有检测的生物标志物均是预后的显著预测因子,无论心肌梗死类型如何。
研究设计与样本
- CHOPIN研究(Copeptin Helps in the early detection Of Patients with acute myocardial INfarction)的回顾性分析。
- 纳入急诊科就诊的胸痛患者2071例,由两名心内科医生裁定T1MI和T2MI。
- 采用受试者工作特征曲线分析评估生物标志物单独或联合鉴别T2MI与T1MI的效能。
- 分析生物标志物对180天随访全因死亡和主要不良心血管事件(急性心肌梗死、不稳定型心绞痛、再梗死、心力衰竭和卒中的复合终点)的预后价值。
主要发现
- 2071例患者中,T1MI 94例,T2MI 176例。
- T1MI患者基线cTnI水平更高,而T2MI患者基线MR-proANP、CT-proET1、MR-proADM和降钙素原水平更高。
- 诊断T2MI的AUC:CT-proET1为0.765,MR-proADM为0.750,MR-proANP为0.733,均高于cTnI的0.631。
- 联合所有生物标志物与使用临床变量联合cTnI的模型鉴别准确度相似(0.854 vs 0.884,P=0.294)。
- 将生物标志物加入临床模型获得最高AUC(0.917)。
关键数值与推荐
- 诊断T2MI的AUC:CT-proET1 0.765、MR-proADM 0.750、MR-proANP 0.733、cTnI 0.631。
- 联合所有生物标志物AUC 0.854,临床变量联合cTnI模型AUC 0.884,差异P=0.294。
- 生物标志物联合临床模型AUC 0.917。
临床怎么用
- 对于急诊胸痛患者,可考虑检测CT-proET1、MR-proADM和MR-proANP以辅助鉴别T2MI与T1MI。
- 除cTnI外的生物标志物有助于T2MI和T1MI的预后风险分层,不受MI类型影响。
- 将生物标志物与临床变量联合可提高T2MI的鉴别效能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The observed incidence of type 2 myocardial infarction (T2MI) is expected to increase with the implementation of increasingly sensitive cTn assays. However, it remains to be determined how to diagnose, risk-stratify, and treat patients with T2MI. We aimed to discriminate and risk-stratify T2MI using biomarkers. METHODS: Patients presenting to the emergency department with chest pain, enrolled in the CHOPIN study (Copeptin Helps in the early detection Of Patients with acute myocardial INfarction), were retrospectively analyzed. Two cardiologists adjudicated type 1 MI (T1MI) and T2MI. The prognostic ability of several biomarkers alone or in combination to discriminate T2MI from T1MI was investigated using receiver operating characteristic curve analysis. The biomarkers analyzed were cTnI, copeptin, MR-proANP (midregional proatrial natriuretic peptide), CT-proET1 (C-terminal proendothelin-1), MR-proADM (midregional proadrenomedullin), and procalcitonin. The prognostic utility of these biomarkers for all-cause mortality and major adverse cardiovascular event (a composite of acute myocardial infarction, unstable angina pectoris, reinfarction, heart failure, and stroke) at 180-day follow-up was also investigated. RESULTS: Among the 2071 patients, T1MI and T2MI were adjudicated in 94 and 176 patients, respectively. Patients with T1MI had higher levels of baseline cTnI, whereas those with T2MI had higher baseline levels of MR-proANP, CT-proET1, MR-proADM, and procalcitonin. The area under the receiver operating characteristic curve for the diagnosis of T2MI was higher for CT-proET1, MR-proADM, and MR-proANP (0.765, 0.750, and 0.733, respectively) than for cTnI (0.631). Combining all biomarkers resulted in a similar accuracy to a model using clinical variables and cTnI (0.854 versus 0.884, P=0.294). Addition of biomarkers to the clinical model yielded the highest area under the receiver operating characteristic curve (0.917). Other biomarkers, but not cTnI, were associated with mortality and major adverse cardiovascular event at 180 days among all patients, with no interaction between the diagnosis of T1MI or T2MI. CONCLUSIONS: Assessment of biomarkers reflecting pathophysiologic processes occurring with T2MI might help differentiate it from T1MI. All biomarkers measured, except cTnI, were significant predictors of prognosis, regardless of the type of myocardial infarction.
引用
- Horiuchi Y, Wettersten N, Patel MP, et al. Biomarkers Enhance Discrimination and Prognosis of Type 2 Myocardial Infarction. Circulation. 2020. PMID: 32820656. doi:10.1161/CIRCULATIONAHA.120.046682
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。